Targeted Delivery of Chemotherapy With Ultrasound and Microbublles
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The oscillations of ultrasound (US) contrast agent microbubbles under their activation by US
waves engender a modulation of the permeability of biological barriers amplifying hence the
extravasation of drugs and/or fluorescent markers through a process known as sonoporation. In
such a way, the bioavailability of the therapeutic agent is augmented only in the area where
US waves are focused. The objective now is to translate this therapeutic approach to the
clinic by performing a feasibility study with the development of a therapy regime optimized
for hepatic metastases of colorectal cancer.
In order to demonstrate the clinical feasibility of the therapeutic approach based on
ultrasound and microbubbles, we will focus on patients with liver metastases of colorectal
cancer treated with monoclonal antibodies in combination with chemotherapy.